FDA, OSHA, and EPA do not wait for a generalist.

Companies do not wake up wanting regulatory help as a category. They wake up because FDA, OSHA, EPA, or a related regime has made delay expensive in a language the rest of the org chart cannot ignore.

Outsiders collapse this into compliance training or a generic checklist. Insiders know the regimes do not share a single skill set. An FDA quality system problem is not an OSHA process-safety problem. An EPA RMP or PFAS exposure issue is not a vendor-risk memo written for a wealth firm. Firms that buy the wrong specialist waste quarters while the inspection clock, the consent timeline, or the customer audit keeps moving.

Enforcement does not have to be maximal to be real. OSHA still runs large programmed inspection volumes in high-risk industries. EPA’s enforcement and compliance planning continues to prioritize chemical safety, accidental release programs, and PFAS-related work under existing statutes even as policy language shifts year to year. FDA pressure shows up as warning letters, import alerts, consent decrees, and customer-driven quality demands long before a headline fine lands.

EPA and OSHA have also formalized coordination on chemical safety under TSCA and workplace health rules. That kind of inter-agency alignment is easy to miss from a board slide and hard to miss when two inspection cultures start asking related questions of the same plant.

The outsider buys a generalist because the invoice looks simpler. The insider buys the person who has already lived the exact framework under which the company is now exposed.

So the work is narrow on purpose: when pressure builds under FDA, OSHA, EPA, or an adjacent regime, connect the firm to counsel or compliance specialists who work that framework, not a one-size compliance product. Timing matters because once a remediation path is chosen badly, reversing it costs more than the original introduction ever would.

Siddham Sehgal

Vayumlabs · Regulatory specialist routing